Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00365898 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain
A Phase 3 study, sponsored by Purdue Pharma.
- Terminated
- Registry status
- Phase 3
- Development phase
- 380
- Enrollment target
NCT00365898 is a Phase 3 study that was terminated before completion, run by Purdue Pharma. The registered enrollment target is 380 participants.
The verdict
NCT00365898, a Phase 3 study, was terminated before completion, sponsored by Purdue Pharma.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 380 participants
- Enrollment target
Study Summary
The objective of this study is to assess the efficacy and safety of 8 mg Hydromorphone Hydrochloride Extended-Release.
Interventions
- DRUG Hydromorphone Hydrochloride Extended-Release
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2005-07 |
| Est. Completion | 2005-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00365898
The ClinicalTrials.gov registry entry for NCT00365898 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Purdue Pharma, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hydromorphone Hydrochloride Extended-Release is the first listed.
NCT00365898 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00365898 about?
NCT00365898 is a clinical study titled "Efficacy and Safety of Hydromorphone Hydrochloride Extended-Release Compared to Placebo in Subjects With Persistent Pain". The objective of this study is to assess the efficacy and safety of 8 mg Hydromorphone Hydrochloride Extended-Release.
What is the current status of trial NCT00365898?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 380 participants. The study started on 2005-07. Estimated completion is 2005-07.
What interventions are being tested in trial NCT00365898?
The interventions under investigation include: Hydromorphone Hydrochloride Extended-Release (DRUG).
Who is sponsoring clinical trial NCT00365898?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.